Avalyn Pharma Inc., a biopharmaceutical company in the clinical stage that specializes in developing inhaled treatments for severe pulmonary diseases, has started a Phase 1b clinical trial to assess the safety, tolerability, and pharmacokinetics...
Prataprao Ganpatrao Jadhav, the Union minister of state for health & family welfare, virtually initiated the second round of the Bi-annual Nationwide Mass Drug Administration (MDA) campaign aimed at eliminating lymphatic filariasis...
Granules India Limited, an Indian pharmaceutical company experiencing rapid growth through vertical integration, reported that the US FDA has granted approval for its ANDA for trazodone hydrochloride tablets USP in various strengths. It has the...
US biotech giant Amgen on Friday announced its plans to open a new technology and innovation site in Hyderabad, India.The site, to be known as Amgen, will be located in HITEC City, a suburb of Hyderabad, occupying six floors of the RMZ Spire Tow...
In today's rapidly evolving technological landscape and the growing intersection of industries, the seemingly unrelated fields of biopharmaceuticals, stainless steel, and cranes actually hold significant potential for innovation and collaboration.
Fortis Healthcare, a key player in healthcare services, has reported a 40.4% increase in net profit to Rs. 174 crore in the first quarter ending June 2024, a comparison to Rs. 124 crore during the corresponding period of the previous financial...
The government no longer requires clinical trials for new drugs that offer major improvements over current standard care and already have regulatory approval in the US, UK, Japan, Australia, Canada or the European Union. The CDSCO stated that...
Praxis Global Alliance states that the Indian diagnostics sector, currently worth approximately $13 billion in FY23, is expected to experience a growth rate of about 14% per year over the next five years. The Indian healthcare industry is on the...
Daiichi Sankyo and Merck, also known as MSD internationally, have broadened their current global collaboration agreement to include Merck's MK-6070, an experimental T-cell engager aimed at delta-like ligand 3 (DLL3), alongside three...
Ocugen, Inc., a biotech company specializing in innovative gene and cell therapies and vaccines, disclosed that FDA has granted approval to initiate its expanded access program for using OCU400 on adult patients, 18 years and above, with retinitis...